Strike Pharma Agreement

Strike Pharma and FyoniBio sign a Master Service Agreement

We are pleased to announce the signing of a Master Service Agreement with Strike Pharma. The project involves the use of the FyoniBio’s versatile CHOnamite® platform to develop and characterize a cell line for a novel, innovative bi-specific therapeutic mAb that has been produced using the Strike Pharma’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology.

Read press release